Recently, with the disclosure of the 2021 annual report, the transfer of shares on the science and innovation board has been gradually liberalized. According to statistics, as of April 28, more than 30 Sci-tech Innovation Board companies have launched stock transfer schemes while implementing cash dividends.
“At present, nearly 60% of the companies on the sci-tech innovation board have less than 50 million shares in free circulation, and 53 Sci-tech Innovation Board companies have a share price of more than 100 yuan, accounting for 44% of the total ‘100 yuan shares’ in the A-share market. The rational implementation of stock transfer is conducive to reducing the stock price, improving the stock liquidity and capital attraction, and stimulating the market vitality. It is not only a necessary means for listed companies to manage liquidity, but also reflects the voice of most investors.” Some market participants told reporters.
transfer to improve trading activity
It is understood that the overall share capital of Kechuang board company is small and the share price is high, and the competitive trading of Kechuang board is 200 shares. The high share price leads to high transaction costs. Many investors have yelled on the SSE e interactive platform that Kechuang board company will implement stock transfer to reduce investment costs and improve stock liquidity.
According to the reporter’s statistics, as of April 28, more than 30 science and Innovation Board companies have launched stock transfer schemes while implementing cash dividends. Among them, Beijing Hotgen Biotech Co.Ltd(688068) also plans to increase 4.8 shares for every 10 shares, which is full of pride.
Beijing Hotgen Biotech Co.Ltd(688068) such generosity may come from the performance of “explosive” growth in 2021. Benefiting from the rapid growth of foreign trade business of covid-19 antigen rapid detection products, the revenue of Beijing Hotgen Biotech Co.Ltd(688068) 2021 increased by 946% year-on-year, and the net profit attributable to the parent increased by 1850% year-on-year, becoming the enterprise with the highest growth rate of net profit on the science and Innovation Board at present.
Kemai shares, with the highest share price of Kechuang board, also launched a profit distribution scheme of “cash dividend + conversion to value-added”. On April 20, the company announced that it planned to distribute a cash dividend of 30 yuan (including tax) for every 10 shares, and increase 4 shares for every 10 shares to all shareholders with the capital reserve. The latest closing price shows that the share price of Hemai shares is as high as 608.05 yuan, second only to Kweichow Moutai Co.Ltd(600519) .
Hemai shares was known as the “most expensive new shares of a shares” at the issuance stage, and the issuance price was as high as 557.80 yuan / share, which deterred many investors who hit the new shares and reluctantly abandoned the purchase. The company’s share price continued to rise after listing, with a maximum of 800 yuan / share.
However, in terms of share capital scale, the total share capital of Hemai shares is only 40 million shares, and the circulating share capital is only 8.8 million shares. The excessively high share price is not conducive to the liquidity of shares in the long run. After the increase, the total share capital of the company will increase to 56 million shares, which will activate the trading activity of the secondary market to a certain extent and attract more capital attention.
year total proposed dividend reaches 28 billion yuan
As of April 28, 396 Sci-tech Innovation Board companies have disclosed their annual performance in 2021, of which more than 300 companies have issued cash dividend plans simultaneously, and the total amount of annual dividends to be distributed has reached 28 billion yuan.
In terms of dividend per share, master biology, Zhejiang Orient Gene Biotech Co.Ltd(688298) , Beijing Hotgen Biotech Co.Ltd(688068) ranked among the top three sectors, and the cash distribution per share reached 10 yuan, 6.18 yuan and 5 yuan respectively. The above three companies are in vitro diagnostic reagent enterprises, and their performance has increased significantly through active research and development and production of nucleic acid detection, antigen detection and other products.
From the perspective of total dividends, the total annual dividends of 63 companies exceeded 100 million yuan, and that of China Railway Signal & Communication Corporation Limited(688009) , Zhuzhou Crrc Times Electric Co.Ltd(688187) , Shenzhen Transsion Holdings Co.Ltd(688036) , Xinjiang Daqo New Energy Co.Ltd(688303) 4 companies exceeded 1 billion yuan. Among them, China Railway Signal & Communication Corporation Limited(688009) continues the tradition of high dividend. The total annual cash dividends in the last three years have reached 2.1 billion yuan, 2.1 billion yuan and 1.8 billion yuan respectively, highlighting the demonstration effect and responsibility of industry leaders.
Xinjiang Daqo New Energy Co.Ltd(688303) listed on the stock market in the first year, it started a large-scale dividend, and it is planned to “pay 6 yuan for 10”, with a cumulative cash dividend of 1.155 billion yuan. High score red is also supported by the strong performance growth of the company. Benefiting from the shortage of silicon material market and the sharp rise of silicon material price and gross profit of the company, Xinjiang Daqo New Energy Co.Ltd(688303) achieved a revenue of 10.832 billion yuan in 2021, with a year-on-year increase of 132.23%, and the net profit attributable to the parent company was 5.724 billion yuan, with a year-on-year increase of 448.56%. In the first quarter, the company’s revenue and net profit attributable to the parent increased by 389.28% and 640.85% respectively.
Insiders said that cash dividend is an important form of investor return, which can enable investors to generate actual cash income, increase capital liquidity and facilitate investors to reallocate resources on this basis. Of course, cash dividends must be based on the company’s profits and sufficient cash flow.
hot track performance strong
On April 28, 30 Sci-tech Innovation Board companies disclosed their annual report for 2021. More than 80% of the enterprises’ income increased, and the track stocks such as innovative drugs, semiconductors and new energy performed well.
Among them, the revenue of innovative pharmaceutical enterprises Bio-Thera Solutions Ltd(688177) , Baiji Shenzhou increased by about 350% and 250% respectively year-on-year; The leader of photovoltaic equipment Qingdao Gaoce Technology Co.Ltd(688556) revenue increased by 110% year-on-year and net profit increased by 193% year-on-year; Guangdong Leadyo Ic Testing Co.Ltd(688135) revenue and net profit attributable to the parent company of domestic sealing and testing manufacturers increased by 55% and 104% respectively.
Meanwhile, on the evening of April 28, 83 Sci-tech Innovation Board companies disclosed their first quarterly reports, and some companies continued to maintain strong performance. For example, Qingdao Gaoce Technology Co.Ltd(688556) , its revenue and net profit attributable to its parent company increased by 103% and 173% respectively.
As a new force in the A-share market, there are nearly 420 Kechuang board companies. According to the disclosed annual report and performance express data, in 2021, the overall operating revenue of the sector increased by 37%, the net profit attributable to the parent increased by 76%, and the overall operating performance maintained steady growth, which has gradually become the main force to activate the driving force of innovation.
